Please note: This is a Sole Source Notification. Oregon State University intends to contract for the provision of CRISPR knock-in cell line development services from EditCo Bio, Inc. as a sole source because of the uniqueness (design, capability, nature) of the services and the contractor being the single provider of the services. The services must include the ability to design and synthesize sgRNAs and donor DNA with clinical rigor, perform CRISPR editing in human cell lines, and validate clones with high specificity and no off-target effects. The vendor must also use proprietary Cas9 and sgRNA components compliant with FDA and ICH GMP regulations, and provide a streamlined path from preclinical to clinical applications. An entity may appeal this determination in accordance with OSU Standard 03-010, Section 5.17 no later than the closing date indicated on the website.
